Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway
Breast and prostate cancer preferentially metastasize in the skeleton, inducinglocally increased bone resorption by osteoclasts. Bisphosphonates (BPs), potent inhibitors of osteoclasts and bone resorption, are able to reduce metastatic bone lesions, but the metastasis-related cellular target molecules for BPs have not yet been identified. In osteoclasts, nitrogen-containing BPs inhibit the functio
